The Top 10 Eastern European Pharmaceutical Companies: Growth strategies, performance and SWOT analyses
Advertisement
http://www.reportlinker.com/p0185309/The-Top-10-Eastern-European-Pharmaceutical-Companies-Growth-strategies-performance-and-SWOT-analyses.html
The Eastern European pharmaceutical companies comprise both Eastern Europe-based and MNCs. This chapter provides an insight into the current state of Eastern European pharmaceutical industry as well as the evolving trends. It also provides the competitive landscape of the industry based on financial and operational (revenue growth over the last five years, exposure to major markets and presence in major therapeutic areas) parameters in the Eastern European region.
Advertisement
The report also includes profiles of the top ten companies in the region and also gives a brief summary of top 11 to 20 players. The top 10 companies in the Eastern European pharmaceutical industry were assessed on following parameters:
Key features of this report
Scope of this report
Key Market Issues
Key findings from this report
Key questions answered
Companies mentioned
Table of Contents
The Top 10 Eastern European Pharmaceutical Companies
Executive summary 14
Industry overview 14
Novartis 15
Sanofi-Aventis 15
GlaxoSmithKline (GSK) 16
Servier 16
Roche 17
Pfizer 17
Bayer 18
Teva 18
Zentiva 19
Krka 19
Chapter 1 Introduction 22
What is this report about? 22
Methodology 22
Chapter 2 Industry overview 24
Summary 24
Introduction 25
Market dynamics 25
Eastern European market: size and growth 25
Parallel trade in Eastern Europe 27
Key market drivers and resistors 28
Competitive landscape 29
Competitive position of the top 10 companies 29
Comparative analysis of the top 10 companies 31
Trends 33
Consolidation underway 33
Increasing use of generics 33
Rise of value added generics and biosimilars 34
Cancer market represents strong commercial opportunity 35
Increasing presence of biotechnology 35
Chapter 3 Novartis 38
Summary 38
Company overview 39
Geographic focus 39
Marketed products 40
Therapeutic focus 40
Research and development 41
Growth strategies 42
Focus on biosimilars 42
Strengthening its oncology portfolio 42
Strengthening presence in Romania 43
Growing business by forging alliances and partnerships 43
Acquisitions and divestments 44
SWOT analysis 45
Chapter 4 Sanofi-Aventis 48
Summary 48
Company overview 49
Geographic focus 49
Marketed products 51
Therapeutic focus 52
Research and development 52
Growth strategies 53
Focusing on external collaborations for business development 53
Acquisitions and divestments 54
SWOT analysis 55
Chapter 5 GSK 58
Summary 58
Company overview 59
Geographic focus 59
Marketed products 61
Therapeutic focus 62
Research and development 62
Growth strategies 63
Investing in product capabilities and R&D 63
Partnerships fostering growth 64
Expanding product portfolio through new drug launches 64
Acquisitions and divestments 65
SWOT analysis 66
Chapter 6 Servier 68
Summary 68
Company overview 69
Geographic focus 69
Marketed products 71
Therapeutic focus 72
Research and development 72
Growth strategies 73
Expanding production capacity and establishing innovative drug development centers 73
Partnerships and alliances to fuel growth 73
Acquisitions and divestments 74
SWOT analysis 75
Chapter 7 Roche 78
Summary 78
Company overview 79
Geographic focus 79
Marketed products 81
Therapeutic focus 82
Research and development 82
Growth strategies 83
Sustaining sales growth for major oncology franchises through lineextensions 83
Diversifying into new therapeutic areas beyond oncology 84
Acquisitions and divestments 84
SWOT analysis 85
Chapter 8 Pfizer 88
Summary 88
Company overview 89
Geographic focus 89
Marketed products 91
Therapeutic focus 92
Research and development 92
Growth strategies 94
Expanding in the under-penetrated Russian market 94
Acquisitions and divestments 94
SWOT analysis 95
Chapter 9 Bayer 98
Summary 98
Company overview 99
Geographic focus 99
Marketed products 101
Therapeutic focus 102
Research and development 102
Growth strategies 103
Realigning focus in healthcare to improve long-term profitability 103
New product development to drive margins in Eastern Europe 104
Acquisitions and divestments 105
SWOT analysis 106
Chapter 10 Teva 108
Summary 108
Company overview 109
Geographic focus 109
Marketed products 110
Therapeutic focus 111
Research and development 111
Growth strategies 112
Leveraging the biosimilar opportunity in Europe 112
Investing in niche specialty areas to drive growth 113
Acquisitions and divestments 113
SWOT analysis 114
Chapter 11 Zentiva 116
Summary 116
Company overview 117
Geographic focus 117
Marketed products 119
Therapeutic focus 120
Research and development 120
Growth strategies 121
Strengthening geographical footprint 121
Improving efficiency to drive profitable growth 122
Acquisitions and divestments 122
SWOT analysis 123
Chapter 12 Krka 126
Summary 126
Company overview 127
Geographic focus 127
Marketed products 129
Therapeutic focus 130
Research and development 130
Growth strategies 131
New product launches fostering growth 131
Expanding production capacity of tablets and injectables and investing in
R&D 132
Fortifying its vertical integrated business to cut manufacturing costs 133
Acquisitions and divestments 133
SWOT analysis 134
Chapter 13 11-20 companies 136
AstraZeneca 136
Company overview 136
Geographic focus 136
Marketed products 137
Therapeutic focus 138
Research and development 140
Gedeon Richter 140
Company overview 140
Geographic focus 141
Marketed products 142
Therapeutic focus 142
Research and development 143
Menarini 144
Company overview 144
Geographic focus 144
Marketed products 146
Therapeutic focus 146
Research and development 147
Schering-Plough 148
Company overview 148
Geographic focus 148
Marketed products 150
Therapeutic focus 150
Research and development 152
Johnson & Johnson (J&J) 152
Company overview 152
Geographic focus 153
Marketed products 155
Therapeutic focus 155
Research and development 157
Eli Lilly 157
Company overview 157
Geographic focus 158
Marketed products 158
Therapeutic focus 159
Research and development 161
Polpharma 162
Company overview 162
Geographic focus 162
Marketed products 163
Therapeutic focus 163
Research and development 164
Boehringer Ingelheim 165
Company overview 165
Geographic focus 165
Marketed products 166
Therapeutic focus 168
Research and development 169
Novo Nordisk 169
Company overview 169
Geographic focus 170
Marketed products 171
Therapeutic focus 171
Research and development 172
Merck & Co. 173
Company overview 173
Geographic focus 173
Marketed products 175
Therapeutic focus 176
Research and development 177
Chapter 14 Appendix 180
Glossary 180
Index 183
List of Figures
Figure 2.1: Eastern European pharmaceutical market size, 2004-08 26
Figure 2.2: Market position of the Eastern European pharmaceutical companies, 2008 27
Figure 2.3: Key market drivers and resistors of Eastern European pharmaceutical market 29
Figure 2.4: Top 10 pharmaceutical companies in Eastern Europe market share, 2008 30
Figure 2.5: Comparative analysis of top 10 companies 32
Figure 3.6: Novartis geographic focus, 2007-08 39
Figure 3.7: Novartis therapeutic focus, 2007-08 41
Figure 3.8: Novartis SWOT analysis 45
Figure 4.9: Sanofi-Aventis geographic focus, 2007-08 50
Figure 4.10: Sanofi-Aventis therapeutic focus, 2007-08 52
Figure 4.11: Sanofi-Aventis SWOT analysis 55
Figure 5.12: GSK geographic focus, 2007-08 60
Figure 5.13: GSK therapeutic focus, 2007-08 62
Figure 5.14: GSK SWOT analysis 66
Figure 6.15: Servier geographic focus, 2007-08 70
Figure 6.16: Servier therapeutic focus, 2007-08 72
Figure 6.17: Servier SWOT analysis 75
Figure 7.18: Roche geographic focus, 2007-08 80
Figure 7.19: Roche therapeutic focus, 2007-08 82
Figure 7.20: Roche SWOT analysis 85
Figure 8.21: Pfizer geographic focus, 2007-08 90
Figure 8.22: Pfizer therapeutic focus, 2007-08 92
Figure 8.23: Pfizer SWOT analysis 95
Figure 9.24: Bayer HealthCare geographic focus, 2007-08 100
Figure 9.25: Bayer HealthCare therapeutic focus, 2007-08 102
Figure 9.26: Bayer HealthCare SWOT analysis 106
Figure 1.1: Teva geographic focus, 2007-08 109
Figure 10.28: Teva therapeutic focus, 2007-08 111
Figure 10.29: Teva SWOT analysis 114
Figure 11.30: Zentiva therapeutic focus, 2007-08 118
Figure 11.31: Zentiva therapeutic focus, 2007-08 120
Figure 11.32: Zentiva SWOT analysis 123
Figure 12.33: Krka geographic focus, 2007-08 128
Figure 12.34: Krka therapeutic focus, 2007-08 130
Figure 12.35: Krka SWOT analysis 134
Figure 13.36: AstraZeneca geographic focus, 2007-08 137
Figure 13.37: AstraZeneca therapeutic focus, 2007-08 139
Figure 13.38: Gedeon Richter geographic focus, 2007-08 141
Figure 13.39: Gedeon Richter therapeutic focus, 2007-08 143
Figure 13.40: Menarini geographic focus, 2007-08 145
Figure 13.41: Menarini therapeutic focus, 2007-08 147
Figure 13.42: Schering-Plough geographic focus, 2007-08 149
Figure 13.43: Schering-Plough therapeutic focus, 2007-08 151
Figure 13.44: J&J geographic focus, 2007-08 154
Figure 13.45: J&J therapeutic focus, 2007-08 156
Figure 13.46: Eli Lilly geographic focus, 2007-08 158
Figure 13.47: Eli Lilly therapeutic focus, 2007-08 160
Figure 13.48: Polpharma therapeutic focus, 2007-08 164
Figure 13.49: Boehringer Ingelheim geographic focus, 2007-08 166
Figure 13.50: Boehringer Ingelheim therapeutic focus, 2007-08 168
Figure 13.51: Novo Nordisk geographic focus, 2007-08 170
Figure 13.52: Novo Nordisk therapeutic focus, 2007-08 172
Figure 13.53: Merck & Co. geographic focus, 2007-08 174
Figure 13.54: Merck & Co. therapeutic focus, 2007-08 176
List of Tables
Table 2.1: Eastern European pharmaceutical market size ($m), 2004-08 25
Table 2.2: Top 10 pharmaceutical companies in Eastern Europe growth (%), 2004-08 31
Table 2.3: Select M&A in Eastern Europe, 2007-09 33
Table 2.4: Select product launches in oncology in Eastern Europe, 2007-08 35
Table 2.5: Presence of biotechnology products in Eastern Europe 36
Table 3.6: Novartis snapshot 38
Table 3.7: Novartis top 10 marketed products sales ($m), 2007-08 40
Table 3.8: Novartis late stage R&D pipeline 42
Table 3.9: Novartis acquisitions and divestments, 2007-09 44
Table 4.10: Sanofi-Aventis snapshot 48
Table 4.11: Sanofi-Aventis top 10 marketed products sales ($m), 2007-08 51
Table 4.12: Sanofi-Aventis late stage R&D pipeline 53
Table 5.13: GSK snapshot 58
Table 5.14: GSK top 10 marketed products sales ($m), 2007-08 61
Table 5.15: GSK late stage R&D pipeline 63
Table 5.16: Select GSK new drug launches, 2007-09 65
Table 6.17: Servier snapshot 68
Table 6.18: Servier top 10 marketed products sales ($m), 2007-08 71
Table 6.19: Servier partnerships and alliances, 2007-09 74
Table 7.20: Roche snapshot 78
Table 7.21: Roche top 10 marketed products sales ($m), 2007-08 81
Table 7.22: Roche late stage R&D pipeline 83
Table 7.23: Roche late stage pipeline products 84
Table 8.24: Pfizer snapshot 88
Table 8.25: Pfizer top 10 marketed products sales ($m), 2007-08 91
Table 8.26: Pfizer's phase III R&D pipeline 93
Table 9.27: Bayer HealthCare snapshot 98
Table 9.28: Bayer HealthCare top 10 marketed products sales ($m), 2007-08 101
Table 9.29: Bayer HealthCare late stage R&D pipeline 103
Table 9.30: Select Bayer HealthCare's product pipeline, 2007-09 105
Table 10.31: Teva snapshot 108
Table 10.32: Teva top 10 marketed products sales ($m), 2007-08 110
Table 10.33: Teva's phase III R&D pipeline 112
Table 10.34: Select Teva's development pipeline in niche specialty areas 113
Table 11.35: Zentiva snapshot 116
Table 11.36: Zentiva top 10 marketed products sales ($m), 2007-08 119
Table 11.37: Select Zentiva new product launches, 2007-08 121
Table 12.38: Krka snapshot 126
Table 12.39: Krka top 10 marketed products sales ($m), 2007-08 129
Table 12.40: Select Krka new drug launches, 2007-09 131
Table 13.41: AstraZeneca snapshot 136
Table 13.42: AstraZeneca top 10 marketed products sales ($m), 2007-08 138
Table 13.43: AstraZeneca late stage R&D pipeline 140
Table 13.44: Gedeon Richter snapshot 140
Table 13.45: Gedeon Richter top 10 marketed products sales ($m), 2007-08 142
Table 13.46: Menarini snapshot 144
Table 13.47: Menarini top 10 marketed products sales ($m), 2007-08 146
Table 13.48: Schering-Plough snapshot 148
Table 13.49: Schering-Plough top 10 marketed products sales ($m), 2007-08 150
Table 13.50: Schering-Plough's phase III R&D pipeline 152
Table 13.51: J&J snapshot 152
Table 13.52: J&J top 10 marketed products sales ($m), 2007-08 155
Table 13.53: J&J's phase III R&D pipeline 157
Table 13.54: Eli Lilly snapshot 157
Table 13.55: Eli Lilly top 10 marketed products sales ($m), 2007-08 159
Table 13.56: Eli Lilly's phase III R&D pipeline 161
Table 13.57: Polpharma snapshot 162
Table 13.58: Polpharma top 10 marketed products sales ($m), 2007-08 163
Table 13.59: Boehringer Ingelheim snapshot 165
Table 13.60: Boehringer Ingelheim top 10 marketed products sales ($m), 2007-08 167
Table 13.61: Boehringer Ingelheim's phase III R&D pipeline 169
Table 13.62: Novo Nordisk snapshot 169
Table 13.63: Novo Nordisk top 10 marketed products sales ($m), 2007-08 171
Table 13.64: Novo Nordisk phase III R&D pipeline 172
Table 13.65: Merck & Co. snapshot 173
Table 13.66: Merck & Co. top 10 marketed products sales ($m), 2007-08 175
Table 13.67: Merck & Co's phase III R&D pipeline 177
To order this report:
Pharmaceutical Industry: The Top 10 Eastern European Pharmaceutical Companies: Growth strategies, performance and SWOT analyses
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
-- Each company's market share in the Eastern European pharmaceutical market; -- Each company's marketed products, geographic and therapeutic focus; -- Each company's growth strategies and major acquisitions and divestments in this market; -- Key mergers and acquisitions formed by these companies; -- Business-related strengths and weaknesses of these companies, and insights into the opportunities and threats facing them.
SOURCE Reportlinker
